ARCHIVES

In Sign-Off Of Two Orphan Drugs, ODAC Leaves Efficacy Interpretation To Docs

This article is from The Cancer Letter archive.

Vol. 24 No. 45 | November 27, 1998

Download PDF Visit The Full Archive

Related Articles

NCI Study Find Farmers Using Herbicides At High Risk for Some Lymphomas

September 12, 1986

Program Monitors Resistance In Antimicrobial And Antifungal Therapies for Cancer Patients

November 29, 2002

National Dialogue plans biospecimen network

July 18, 2003

Pretreatment with Azacitidine Achieves 28-Month Remission

August 30, 2013

FDA Approves Velcade For Treatment Of Refractory Multiple Myeloma

May 30, 2003

Organ Systems Support Contract To Cost More than OSCC Grant

September 30, 1988